Sfoglia per AUTORE
MOLICA S
Collezione ASL Asti

  

Items : 9

OBINUTUZUMAB PLUS CHLORAMBUCIL VERSUS IBRUTINIB IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA WITHOUT TP53 DISRUPTIONS. A CAMPUS CLL STUDY in Haematologica

2021
ASL Asti

Visentin A; Pravato S; Mauro FR; Pietrasanta D; Fresa A; Vitale C; Ciolli S; Cassin R; Cibien F; Sportoletti P; Gentile M; Rigolin GM; Quaglia FM; Murru R; Gozzetti A; Molica S; Marchetti M; Scarfò L; Guardalben E; Avitabile A; Reda G; Coscia M; Laurenti L; Pizzolo G; Semenzato G; Foà R; Cuneo A; Trentin L;

Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. in Cancer medicine / Cancer Med. 2020 Nov;9(22):8468-8479. doi: 10.1002/cam4.3470. Epub 2020 Sep 24.

2020
ASL Asti
AOU Città della Salute di Torino
ASL Vercelli
AO Cuneo
AOU Novara

Vignetti M; Foà R; Ghia P; Cimino G; Cavallari M; Cucci R; de la Serna J; Ferrarini I; Medina Perez A; Mauro FR; Coscia M; Di Raimondo F; Farina L; Molica S; Gaidano G; Doubek M; Ilariucci F; Tedeschi A; Marchetti M; Spacek M; Trentin L; Billio A; Ujjani CS; Roeker L; Orlandi EM; Schuster SJ; Shah NN; Sehgal AR; Pu JJ; et alii...

Complex Karyotype Is Associated with A Less Favorable Outcome after Ibrutinib and Rituximab As Front-Line Treatment of Unfit Patients with Chronic Lymphocytic Leukemia (GIMEMA LLC1114) in Haematologica

2020
ASL Asti

Del Giudice I; Rigolin GM; Bardi A; Melandri A; Cavallari M; Raponi S; Ilari C; Cafforio L; Piciocchi A; Arena V; Fabri S; Albano F; Nanni M; Molica S; Reda G; Sportoletti M; Trentin L; Marchetti M; Peragine N; Mariglia P; Vignetti M; Mauro FR; Guarini A; Foà R; Cuneo A;

Retrospective Real-Life Comparison of Obinutuzumab Plus Chlorambucil Versus Ibrutinib in Previously Untreated and Unfit Patients with Chronic Lymphocytic Leukemia without TP53 Disruptions. Interim Results from the Italian CLL Campus in Blood

2020
ASL Asti
AOU Città della Salute di Torino

Visentin A; Mauro FR; Pietrasanta D; Fresa A; Vitale C; Ciolli S; Cassin R; Cibien F; Sportoletti P; Gentile M; Rigolin GM; Quaglia FM; Murru R; Gozzetti A; Molica S; Marchetti M; Scarfo L; Reda G; Coscia M; Laurenti L; Pizzolo G; Semenzato G; Foà R; Cuneo A; Trentin L;

Efficacy and safety of front-line treatment with ibrutinib and rituximab in unfit patients with chronic lymphocytic leukemia (CLL). First report of the GIMEMA LLC1114 study in Haematologica

2019
ASL Asti
AO Ordine Mauriziano

Mauro FR; Molica S; Paoloni F; Reda G; Trentin L; Marchetti M; Pietrasanta D; Coscia M; Marasca R; Sportoletti P; Gaidano G; Orsucci L; Stelitano C; Di Renzo N; Liberati M; Gottardi D; Re F; Ilariucci F; Zinzani PL; Mannina D; Gozzetti A; Molinari AL; Gentile M; Chiarenza A; Laurenti L; Varettoni M; Ibatici A; Murru R; Tani M; et alii...

Ibrutinib and rituximab as front-line treatment for unfit patients with chronic lymphocytic leukemia (CLL). preliminary results from the Gimema LLC1114 study in HemaSphere

2019
AO Ordine Mauriziano
ASL Asti

Mauro FR; Molica S; Paoloni F; Reda G; Trentin L; Marchetti M; Pietrasanta D; Coscia M; Marasca R; Sportoletti P; Gaidano G; Orsucci L; Stelitano C; Di Renzo N; Liberati AM; Gottardi D; Re F; Ilariucci F; Zinzani P; Mannina D; Gozzetti A; Molinari AL; Gentile M; Consoli U; Laurenti L; Arcaini L; Ibatici A; Murru R; Tani M; et alii...

Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study. in Haematologica / Haematologica. 2018 Jul;103(7):1209-1217. doi: 10.3324/haematol.2018.189837. Epub 2018 Apr 19.

2018
ASL Asti
AOU Città della Salute di Torino
ASL Vercelli

Eyre TA; Kennedy B; Schuh A; Smolej L; Montillo M; Cortelezzi A; Ciolli S; Forconi F; Gonzalez M; Re F; Gaidano G; Molica S; Marchetti M; Ilariucci F; Meneghini V; Chiarenza A; Marasca R; Amendola A; Billio A; Visco C; Mauro FR; Galieni P; Orlandi EM; Farina L; Delgado AR; Musuraca G; Laurenti L; Coscia M; Perez AM; et alii...

Efficacy and safety of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia: Results of the GIMEMA-ERIC LLC1315 study in Blood

2017
ASL Asti

Ghia P; Foa R; Follows GA; De La Serna J; Vignetti M; Gaidano G; Ilariucci F; Meneghini V; Chiarenza A; González M; Re F; Marchetti M; Marasca R; Pizzuti M; Visco C; Ciolli S; Orlandi EM; Rivas-Delgado A; Farina L; Musuraca G; Coscia M; Perez AM; Trentin L; Gentile M; Montillo M; Molica S; Mauro FR; Laurenti L; Galieni P; et alii...

Appropriate use of bendamustine in first-line therapy of chronic lymphocytic leukemia. Recommendations from SIE, SIES, GITMO Group. in Leukemia research / Leuk Res. 2014 Nov;38(11):1269-77. doi: 10.1016/j.leukres.2014.06.017. Epub 2014 Jul 7.

2014
ASL Asti

Cuneo A; Marchetti M; Barosi G; Billio A; Brugiatelli M; Ciolli S; Laurenti L; Mauro FR; Molica S; Montillo M; Zinzani P; Tura S;